CRISPR THERAPEUTICS AG Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
CRISPR THERAPEUTICS AG (CRSP) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 875.53 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-03
- CRISPR THERAPEUTICS AG share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 158.60K shares, a 8.93% increase year-over-year.
- CRISPR THERAPEUTICS AG share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 716.93K shares, a 19.87% decline year-over-year.
- CRISPR THERAPEUTICS AG share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 319.13K shares, a 34.30% decline year-over-year.
- CRISPR THERAPEUTICS AG share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 32.00K shares, a 30.08% increase year-over-year.
- CRISPR THERAPEUTICS AG share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 1.39M shares, a 11.18% decline from fiscal 2024.
- CRISPR THERAPEUTICS AG share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 1.57M shares, a 15.80% decline from fiscal 2023.
- CRISPR THERAPEUTICS AG share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 1.86M shares, a 24.65% increase from fiscal 2022.
- CRISPR THERAPEUTICS AG share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 1.49M shares, a 7.65% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 158.60K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | 875.53K shares 10-Q · filed 2026-08-03 | 1.19M shares derived: sum of 3 quarters · filed 2026-08-03 | 1.23M shares derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | 716.93K shares 10-Q · filed 2026-05-04 | 1.04M shares derived: sum of 2 quarters · filed 2026-05-04 | 1.07M shares derived: sum of 3 quarters · filed 2026-05-04 | 1.21M shares derived: sum of 4 quarters · filed 2026-05-04 |
| 2025-12-31 | 319.13K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | 351.13K shares derived: sum of 2 quarters · filed 2026-02-12 | 496.73K shares derived: sum of 3 quarters · filed 2026-02-12 | 1.39M shares 10-K · filed 2026-02-12 |
| 2025-09-30 | 32.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | 177.60K shares derived: sum of 2 quarters · filed 2025-11-10 | 1.07M shares 10-Q · filed 2025-11-10 | 1.56M shares derived: sum of 4 quarters · filed 2026-02-12 |
| 2025-06-30 | 145.60K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | 1.04M shares 10-Q · filed 2025-08-04 | 1.53M shares derived: sum of 3 quarters · filed 2026-02-12 | 1.55M shares derived: sum of 4 quarters · filed 2026-02-12 |
| 2025-03-31 | 894.65K shares 10-Q · filed 2025-05-06 | 1.38M shares derived: sum of 2 quarters · filed 2026-02-12 | 1.40M shares derived: sum of 3 quarters · filed 2026-02-12 | 1.65M shares derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-12-31 | 485.71K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | 510.31K shares derived: sum of 2 quarters · filed 2026-02-12 | 754.91K shares derived: sum of 3 quarters · filed 2026-02-12 | 1.57M shares 10-K · filed 2026-02-12 |
| 2024-09-30 | 24.60K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | 269.20K shares derived: sum of 2 quarters · filed 2024-11-05 | 1.08M shares 10-Q · filed 2024-11-05 | 1.56M shares derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-06-30 | 244.60K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | 1.06M shares 10-Q · filed 2024-08-05 | 1.53M shares derived: sum of 3 quarters · filed 2026-02-12 | 1.56M shares derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-03-31 | 811.62K shares 10-Q · filed 2024-05-08 | 1.29M shares derived: sum of 2 quarters · filed 2026-02-12 | 1.31M shares derived: sum of 3 quarters · filed 2026-02-12 | 1.44M shares derived: sum of 4 quarters · filed 2026-02-12 |
| 2023-12-31 | 477.30K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | 501.70K shares derived: sum of 2 quarters · filed 2026-02-12 | 623.60K shares derived: sum of 3 quarters · filed 2026-02-12 | 1.86M shares 10-K · filed 2026-02-12 |
| 2023-09-30 | 24.40K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | 146.30K shares derived: sum of 2 quarters · filed 2023-11-06 | 1.38M shares 10-Q · filed 2023-11-06 | 1.73M shares derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-06-30 | 121.90K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | 1.36M shares 10-Q · filed 2023-08-07 | 1.71M shares derived: sum of 3 quarters · filed 2025-02-11 | 1.74M shares derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-03-31 | 1.24M shares 10-Q · filed 2023-05-08 | 1.59M shares derived: sum of 2 quarters · filed 2025-02-11 | 1.62M shares derived: sum of 3 quarters · filed 2025-02-11 | 1.91M shares derived: sum of 4 quarters · filed 2025-02-11 |
| 2022-12-31 | 348.60K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-11 | 382.15K shares derived: sum of 2 quarters · filed 2025-02-11 | 672.40K shares derived: sum of 3 quarters · filed 2025-02-11 | 1.49M shares 10-K · filed 2025-02-11 |
| 2022-09-30 | 33.55K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | 323.80K shares derived: sum of 2 quarters · filed 2022-11-01 | 1.14M shares 10-Q · filed 2022-11-01 | 1.63M shares derived: sum of 4 quarters · filed 2024-02-21 |
| 2022-06-30 | 290.25K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | 1.11M shares 10-Q · filed 2022-08-08 | 1.60M shares derived: sum of 3 quarters · filed 2024-02-21 | 1.65M shares derived: sum of 4 quarters · filed 2024-02-21 |
| 2022-03-31 | 820.19K shares 10-Q · filed 2022-05-09 | 1.31M shares derived: sum of 2 quarters · filed 2024-02-21 | 1.36M shares derived: sum of 3 quarters · filed 2024-02-21 | 1.55M shares derived: sum of 4 quarters · filed 2024-02-21 |
| 2021-12-31 | 486.10K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | 541.80K shares derived: sum of 2 quarters · filed 2024-02-21 | 733.70K shares derived: sum of 3 quarters · filed 2024-02-21 | 1.62M shares 10-K · filed 2024-02-21 |
| 2021-09-30 | 55.70K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | 247.60K shares derived: sum of 2 quarters · filed 2021-11-03 | 1.13M shares 10-Q · filed 2021-11-03 | 1.84M shares derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-06-30 | 191.90K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | 1.07M shares 10-Q · filed 2021-07-29 | 1.79M shares derived: sum of 3 quarters · filed 2023-02-21 | 2.08M shares derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-03-31 | 882.56K shares 10-Q · filed 2021-04-27 | 1.60M shares derived: sum of 2 quarters · filed 2023-02-21 | 1.89M shares derived: sum of 3 quarters · filed 2023-02-21 | 2.18M shares derived: sum of 4 quarters · filed 2023-02-21 |
| 2020-12-31 | 714.01K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | 1.01M shares derived: sum of 2 quarters · filed 2023-02-21 | 1.30M shares derived: sum of 3 quarters · filed 2023-02-21 | 2.18M shares 10-K · filed 2023-02-21 |
| 2020-09-30 | 295.30K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-28 | 581.30K shares derived: sum of 2 quarters · filed 2020-10-28 | 1.47M shares 10-Q · filed 2020-10-28 | 2.16M shares derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-06-30 | 286.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-27 | 1.17M shares 10-Q · filed 2020-07-27 | 1.87M shares derived: sum of 3 quarters · filed 2022-02-15 | 2.06M shares derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-03-31 | 887.46K shares 10-Q · filed 2020-04-28 | 1.58M shares derived: sum of 2 quarters · filed 2022-02-15 | 1.77M shares derived: sum of 3 quarters · filed 2022-02-15 | 2.17M shares derived: sum of 4 quarters · filed 2022-02-15 |
| 2019-12-31 | 695.91K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | 884.01K shares derived: sum of 2 quarters · filed 2022-02-15 | 1.29M shares derived: sum of 3 quarters · filed 2022-02-15 | 2.83M shares 10-K · filed 2022-02-15 |
| 2019-09-30 | 188.10K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-28 | 591.30K shares derived: sum of 2 quarters · filed 2019-10-28 | 2.14M shares 10-Q · filed 2019-10-28 | |
| 2019-06-30 | 403.20K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-29 | 1.95M shares 10-Q · filed 2019-07-29 | ||
| 2019-03-31 | 1.55M shares 10-Q · filed 2019-04-29 | |||
| 2018-12-31 | 2.21M shares 10-K · filed 2021-02-16 | |||
| 2017-12-31 | 3.00M shares 10-K · filed 2020-02-12 | |||
| 2016-09-30 | 1.85M shares 10-Q · filed 2016-11-22 | |||
| 2015-09-30 | 1.70M shares 10-Q · filed 2016-11-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |